Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Non-Current Assets (2016 - 2023)

CNBX Pharmaceuticals (CNBX) has disclosed Non-Current Assets for 10 consecutive years, with $236466.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non-Current Assets fell 53.62% year-over-year to $236466.0, compared with a TTM value of $236466.0 through Aug 2024, down 83.7%, and an annual FY2023 reading of $274731.0, down 55.17% over the prior year.
  • Non-Current Assets was $236466.0 for Q4 2023 at CNBX Pharmaceuticals, down from $274731.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $14.6 million in Q2 2019 and bottomed at $236466.0 in Q4 2023.
  • Average Non-Current Assets over 5 years is $3.0 million, with a median of $1.3 million recorded in 2020.
  • The sharpest move saw Non-Current Assets skyrocketed 1657.52% in 2019, then tumbled 89.77% in 2020.
  • Year by year, Non-Current Assets stood at $3.4 million in 2019, then tumbled by 60.65% to $1.3 million in 2020, then dropped by 14.14% to $1.2 million in 2021, then crashed by 55.88% to $509824.0 in 2022, then plummeted by 53.62% to $236466.0 in 2023.
  • Business Quant data shows Non-Current Assets for CNBX at $236466.0 in Q4 2023, $274731.0 in Q3 2023, and $313223.0 in Q2 2023.